Topical thiotepa treatment for recurrent corneal haze after photorefractive keratectomy.
OBJECTIVE
To describe the use of topical thiotepa in the treatment of recurrent haze after photorefractive keratectomy (PRK).


METHODS
Gimbel Eye Centre, Calgary, Alberta, Canada.


METHODS
Five patients with recurrent haze after myopic PRK were retreated with phototherapeutic keratectomy and topical thiotepa. Before retreatment, the best corrected visual acuity (BCVA) ranged from 20/40 to 20/200. Follow-up ranged from 3 to to15 months.


RESULTS
Haze, uncorrected visual acuity (UCVA), and BCVA improved in all patients. Three eyes had a UCVA of 20/20(-2) or better and a BCVA of 20/20(-1) or better. The other 2 eyes experienced regression of the myopia and astigmatism and had a BCVA of 20/25(-1) or better.


CONCLUSIONS
Topical thiotepa appeared to be an effective treatment for recurrent corneal haze following myopic PRK.
Anderson Penno
Ellen
E
Gimbel Eye Centre, Calgary, Alberta, Canada. eepenno@gimbel.com
Braun
Dennis A
DA
Kamal
Aasim
A
Hamilton
W Keith
WK
Gimbel
Howard V
HV
D000287:Administration, Topical; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D001251:Astigmatism / Q000503:physiopathology / Q000601:surgery; D003318:Corneal Opacity / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D054018:Lasers, Excimer; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000503:physiopathology / Q000601:surgery; D009883:Ophthalmic Solutions; D018903:Photorefractive Keratectomy / Q000009:adverse effects*; D011183:Postoperative Complications; D012008:Recurrence; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use*; D014792:Visual Acuity
D018906:Antineoplastic Agents, Alkylating; D009883:Ophthalmic Solutions; D013852:Thiotepa